Bullish Case: Positive KB113 Gorlin syndrome early data (Oct 15) adds a second pipeline leg beyond Vyjuvek, call volume is 96% above puts, bullish risk is 16% higher across tenors, and Helium's density peaks near $330-340 (above the $316.58 spot). BofA's $400 target and Helium's 2027 IV rising to ~53% signal event-rich upside into readouts.

Bearish Case: KRYS is down 6.5% in a month on mean-reverting price action, Q2 revenue missed, and the density surface shows a sharp market-implied cliff below $330 with meaningful downside mass. Elevated ~49% flat IV prices binary trial/safety risk, payer friction on Vyjuvek's reimbursement-driven model, and any dilution or readout miss could trigger fast -25%+ repricing.

Potential Outcomes:

1. Positive KB113/Vyjuvek momentum — 30%: follow-on data or beats push $340-380.
2. Range/mean reversion — 34%: no catalyst; $300-335 (falsifiable: realized < 49% IV by Dec 19).
3. Reimbursement/competitive pressure — 18%: $270-300.
4. Setback/dilution — 12%: trial hold or raise; < $270.
5. Pure IV crush post-event — 6%: sideways as vol compresses.

October 17, 2026